The R-RAS2 GTPase Is a Signaling Hub in Triple-Negative Breast Cancer Cell Metabolism and Metastatic Behavior

Investigators established R-RAS2 as a central driver of TNBC malignancy and highlight its potential as a promising therapeutic target, particularly in aggressive, postpartum-associated breast cancers.